Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An Overview of Emerging Immunotargets of Genitourinary Tumors.
Montironi R, Santoni M, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Scarpelli M. Montironi R, et al. Among authors: matrana mr. Curr Drug Targets. 2016;17(7):750-6. doi: 10.2174/1389450117666151209144649. Curr Drug Targets. 2016. PMID: 26648079 Review.
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, Occhipinti G, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Principato G, Cascinu S, Montironi R. Piva F, et al. Among authors: matrana mr. Expert Rev Mol Diagn. 2015;15(9):1201-10. doi: 10.1586/14737159.2015.1068122. Epub 2015 Jul 11. Expert Rev Mol Diagn. 2015. PMID: 26166446 Review.
Emerging Immunotargets in Metastatic Renal Cell Carcinoma.
Kucharczyk J, Matrana MR, Santoni M, Massari F, Scarpelli M, Cheng L, Lopez-Beltran A, Cascinu S, Montironi R, Holger M. Kucharczyk J, et al. Among authors: matrana mr. Curr Drug Targets. 2016;17(7):771-6. doi: 10.2174/1389450117666151209115753. Curr Drug Targets. 2016. PMID: 26648075 Review.
Emerging Immunotargets in Bladder Cancer.
Massari F, Ciccarese C, Vau N, Santoni M, Montironi R, Cheng L, Marques RC, Scarpelli M, Fonseca J, Matrana MR, Holger M, Cascinu S, Tortora G, Lopez-Beltran A. Massari F, et al. Among authors: matrana mr. Curr Drug Targets. 2016;17(7):757-70. doi: 10.2174/1389450117666160201105537. Curr Drug Targets. 2016. PMID: 26844572
Emerging Immunotargets and Immunotherapies in Prostate Cancer.
Montironi R, Santoni M, Sotte V, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Berardi R, Scarpelli M. Montironi R, et al. Among authors: matrana mr. Curr Drug Targets. 2016;17(7):777-82. doi: 10.2174/1389450117666160217123304. Curr Drug Targets. 2016. PMID: 26898309 Review.
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.
Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, Matrana MR, Cartenì G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A, Montironi R, Battelli N. Santoni M, et al. Among authors: matrana mr. Cancers (Basel). 2019 Dec 30;12(1):84. doi: 10.3390/cancers12010084. Cancers (Basel). 2019. PMID: 31905816 Free PMC article.
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
Santoni M, Massari F, Bracarda S, Procopio G, Milella M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Rizzo M, Cartenì G, Grande E, Matrana MR, Crabb SJ, Vau N, Sorgentoni G, Cimadamore A, Montironi R, Battelli N. Santoni M, et al. Among authors: matrana mr. Diagnostics (Basel). 2021 Jan 18;11(1):138. doi: 10.3390/diagnostics11010138. Diagnostics (Basel). 2021. PMID: 33477676 Free PMC article.
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study.
Santoni M, Massari F, Grande E, Procopio G, Matrana MR, Rizzo M, De Giorgi U, Basso U, Milella M, Iacovelli R, Aurilio G, Incorvaia L, Buti S, Caffo O, Fornarini G, Carrozza F, Mollica V, Rizzo A, Farag F, Molina-Cerrillo J, Battelli N. Santoni M, et al. Among authors: matrana mr. Target Oncol. 2021 Sep;16(5):625-632. doi: 10.1007/s11523-021-00828-z. Epub 2021 Aug 2. Target Oncol. 2021. PMID: 34338966
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma.
Mollica V, Santoni M, Matrana MR, Basso U, De Giorgi U, Rizzo A, Maruzzo M, Marchetti A, Rosellini M, Bleve S, Maslov D, Tawagi K, Philon E, Blake Z, Massari F. Mollica V, et al. Among authors: matrana mr. Target Oncol. 2022 Jan;17(1):61-68. doi: 10.1007/s11523-021-00861-y. Epub 2021 Dec 11. Target Oncol. 2022. PMID: 34894318
71 results